All In Biotech

Drug Trial Radar · NCT01756456

Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.

An 8-week Phase I/II, Multicenter, Randomized, Double-masked, Vehicle Controlled Parallel Group Study to Evaluate the Safety and Efficacy of Two Doses of Recombinant Human Nerve Growth Factor in Patients With Stage 2 and 3 of NK

Last checked: Nov 20, 2026Latest source record: Apr 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 174 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

174

Actual

Start

Jan 2013

Primary completion

Apr 2015

Study completion May 2016

Sponsor

Lead sponsor
Dompé Farmaceutici S.p.AIndustry
Sponsor type
Industry
First posted
Dec 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is aimed at assessing the safety and the efficacy of two dose regimens of recombinant human nerve growth factor (rhNGF) eye drops solution compared to vehicle for inducing a complete healing of stage 2 (persistent epithelial defect) and 3 (corneal ulcer) neurotrophic keratitis

Conditions

  • Neurotrophic Keratitis
  • Keratitis
  • Corneal Ulcer

Interventions

  • rhNGF 10 μg/mlDrug

    rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)

  • rhNGF 20 μg/mlDrug

    one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)

  • vehicleOther

    ophthalmic solution of the same composition as the test product without rhNGF

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Achieving Healing of the Persistent Epithelial Defect (PED) or Corneal UlcerTime frame: at 4 weeks of treatment

Locations

34 sites in 6 countries. Site status is shown where the registry gives one.

  • CHU de Dijon - Service ophtalmologie

    Dijon, France

  • CHU Dupuytren - Service Ophtalmologie

    Limoges, France

  • Centre Hospitalier National d'Ophtalmologie - Service d'ophtalmologie

    Paris, France

  • "Fondation Ophtalmologique Adolphe de Rothschild - "Unité de Recherche Clinique

    Paris, France

  • "CHU Toulouse-Purpan - Service Ophtalmologie

    Toulouse, France

  • Universität zu Köln - Zentrum für Augenheilkunde am Universitätsklinikum Köln

    Cologne, Germany

  • University Eye Clinic in Düsseldorf

    Düsseldorf, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Universitäts-Augenklinik Freiburg

    Freiburg im Breisgau, Germany

  • Johannes-Gutenberg-Universität Augenklinik und Poliklinik - Department of Ophthalmology

    Mainz, Germany

  • Klinikum der Universität München - Augenklinik der Ludwig-Maximilians-Universtiät München

    München, Germany

  • Università G. D' Annunzio - Clinica Oftalmologica - Centro regionale di Eccellenza in Oftalmologia

    Chieti, Italy

  • Azienda Ospedaliero Universitaria Careggi

    Florence, Italy

  • Dipartimento di Scienze Neurologiche Oftalmologia e Genetica - Universtità di Genova

    Genoa, Italy

  • Azienda Ospedaliero Universitaria di Messina - Dipartimento Specialità Chirurgiche Ambulatorio Studio delle Malattie dela Superficie Oculare Unità Operativa Complessa di Oftalmologia

    Messina, Italy

  • Azienda Ospedaliera San Paolo - U.O. Oculistica

    Milan, Italy

  • Azienda ospedaliera di Padova - Clinica Oculistica Policlinico 7° Piano

    Padova, Italy

  • Università Campus Bio-Medico di Roma

    Rome, Italy

  • Policlinico Umberto I

    Rome, Italy

  • OSPEDALE SAN RAFFAELE di Milano

    Milan, Lombardy, Italy

  • District Railway Hospital Katowice - Department of Ophthalmology

    Katowice, Poland

  • "SPKSO Szpital Okulistyczny ul. - SPKSO Szpital Okulistyczny

    Warsaw, Poland

  • Vissum Corporación Oftalmológica de Alicante

    Alicante, Spain

  • Hospital de Cruces - Oftalmología

    Barakaldo, Spain

  • Barraquer Eye center

    Barcelona, Spain

  • Hospital Clinic de Barcelona - Oftalmología

    Barcelona, Spain

  • Hospital Clínico San Carlos - Oftalmología. Unidad de Superficie Ocular

    Madrid, Spain

  • Instituto Oftalmológico Fernández-Vega - Oftalmología

    Oviedo, Spain

  • Cartuja Visión - Oftalmología

    Seville, Spain

  • University of Birmingham - Academic Unit of Ophthalmology, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham

    Birmingham, United Kingdom

  • Moorfields Eye Hospital - Moorfields Eye Hospital

    London, United Kingdom

  • Manchester Royal Eye Hospital - Manchester Royal Eye Hospital

    Manchester, United Kingdom

  • Royal Victoria Infirmary - Dept. of Ophthalmology

    Newcastle upon Tyne, United Kingdom

  • University of Southampton Southampton General Hospital - MP104, Eye Unit

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.